161 related articles for article (PubMed ID: 37389827)
41. Soluble CD163 and interleukin-6 are increased in aqueous humour from patients with endothelial rejection of corneal grafts.
Funding M; Vorum H; Nexø E; Moestrup SK; Ehlers N; Møller HJ
Acta Ophthalmol Scand; 2005 Apr; 83(2):234-9. PubMed ID: 15799739
[TBL] [Abstract][Full Text] [Related]
42. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
43. Elevated soluble CD163 plasma levels are associated with disease severity in patients with hemorrhagic fever with renal syndrome.
Wang J; Guo W; Du H; Yu H; Jiang W; Zhu T; Bai X; Wang P
PLoS One; 2014; 9(11):e112127. PubMed ID: 25392926
[TBL] [Abstract][Full Text] [Related]
44. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
[TBL] [Abstract][Full Text] [Related]
45. CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients.
Miao Y; Lin P; Saksena A; Xu J; Wang M; Romaguera J; Yin CC; Medeiros LJ; Li S
Am J Surg Pathol; 2019 Aug; 43(8):1052-1060. PubMed ID: 31045891
[TBL] [Abstract][Full Text] [Related]
46. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
48. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).
Stefoni V; Pellegrini C; Broccoli A; Baldini L; Tani M; Cencini E; Figuera A; Ansuinelli M; Bernocco E; Cantonetti M; Cox MC; Ballerini F; Rusconi C; Visco C; Arcaini L; Fama A; Marasca R; Volpetti S; Castellino A; Califano C; Cavaliere M; Gini G; Liberati AM; Musuraca G; Lucania A; Ricciuti G; Argnani L; Zinzani PL
Oncologist; 2018 Sep; 23(9):1033-1038. PubMed ID: 29674440
[TBL] [Abstract][Full Text] [Related]
49. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus.
Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Sakai K; Inoue Y; Ihn H
Eur J Dermatol; 2012; 22(4):512-7. PubMed ID: 22576016
[TBL] [Abstract][Full Text] [Related]
50. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
[TBL] [Abstract][Full Text] [Related]
51. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
52. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
[TBL] [Abstract][Full Text] [Related]
53. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.
Semnani-Azad Z; Connelly PW; Johnston LW; Retnakaran R; Harris SB; Zinman B; Hanley AJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):e285-94. PubMed ID: 31677389
[TBL] [Abstract][Full Text] [Related]
54. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.
Sarkozy C; Terré C; Jardin F; Radford I; Roche-Lestienne C; Penther D; Bastard C; Rigaudeau S; Pilorge S; Morschhauser F; Bouscary D; Delarue R; Farhat H; Rousselot P; Hermine O; Tilly H; Chevret S; Castaigne S
Genes Chromosomes Cancer; 2014 Jan; 53(1):106-16. PubMed ID: 24249260
[TBL] [Abstract][Full Text] [Related]
55. Potential role of tumor-associated macrophages and CD163/CD68 ratio in mycosis fungoides and Sézary syndrome in correlation with serum sCD163 and CCL22.
El-Guindy DM; Elgarhy LH; Elkholy RA; Ali DA; Helal DS
J Cutan Pathol; 2022 Mar; 49(3):261-273. PubMed ID: 34687561
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer.
No JH; Moon JM; Kim K; Kim YB
Gynecol Obstet Invest; 2013; 75(4):263-7. PubMed ID: 23595052
[TBL] [Abstract][Full Text] [Related]
57. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
58. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
59. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Wang M; Fayad L; Wagner-Bartak N; Zhang L; Hagemeister F; Neelapu SS; Samaniego F; McLaughlin P; Fanale M; Younes A; Cabanillas F; Fowler N; Newberry KJ; Sun L; Young KH; Champlin R; Kwak L; Feng L; Badillo M; Bejarano M; Hartig K; Chen W; Chen Y; Byrne C; Bell N; Zeldis J; Romaguera J
Lancet Oncol; 2012 Jul; 13(7):716-23. PubMed ID: 22677155
[TBL] [Abstract][Full Text] [Related]
60. Downregulation of CD163 in monocytes and its soluble form in the plasma is associated with a pro-inflammatory profile in pregnant women with preeclampsia.
Nunes PR; Romão-Veiga M; Peraçoli JC; Araujo Costa RA; de Oliveira LG; Borges VTM; Peraçoli MT
Immunol Res; 2019 Jun; 67(2-3):194-201. PubMed ID: 31240481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
